ATE237697T1 - Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit - Google Patents

Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit

Info

Publication number: ATE237697T1
Authority: AT; Austria
Prior art keywords: effectiveness; vitro; tumors; reproduce; predicting
Prior art date: 1993-06-29

Application number

AT94922483T

Other languages

English (en)

Inventor

Kenneth M Connors

Anna Monosov

Original Assignee

Anticancer Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-29

Filing date

1994-06-29

Publication date

2003-05-15

1994-06-29 Application filed by Anticancer Inc filed Critical Anticancer Inc

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE237697T1 publication Critical patent/ATE237697T1/de

Links

238000000034 method Methods 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title abstract 2
238000000338 in vitro Methods 0.000 title abstract 2
230000004083 survival effect Effects 0.000 title 1
230000003833 cell viability Effects 0.000 abstract 2
239000002246 antineoplastic agent Substances 0.000 abstract 1
229940041181 antineoplastic drug Drugs 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT94922483T 1993-06-29 1994-06-29 Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit ATE237697T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8440293A	1993-06-29	1993-06-29
PCT/US1994/007476 WO1995001455A1 (en)	1993-06-29	1994-06-29	NATIVE-STATE METHOD AND SYSTEM FOR DETERMINING VIABILITY AND PROLIFERATIVE CAPACITY OF TISSUES $i(IN VITRO)

Publications (1)

Publication Number	Publication Date
ATE237697T1 true ATE237697T1 (de)	2003-05-15

Family

ID=22184744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94922483T ATE237697T1 (de)	1993-06-29	1994-06-29	Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit

Country Status (5)

Country	Link
EP (1)	EP0714448B1 (de)
AT (1)	ATE237697T1 (de)
AU (1)	AU7357894A (de)
DE (1)	DE69432517T2 (de)
WO (1)	WO1995001455A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60327359D1 (de) *	2002-11-12	2009-06-04	Anticancer Inc	Erstellung von expressionsprofilen auf der grundlage von histokulturen
EP4271995A4 (de) *	2020-12-31	2024-11-20	Elephas Biosciences Corporation	Ex-vivo-systeme und verfahren zur bestimmung der wirkung eines arzneimittels oder eines anderen mittels auf ein gewebe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0467885A4 (en) *	1989-03-20	1993-03-31	Anticancer Inc.	Native-state method and system for determining viability and proliferative capacity of tissues -i(in vitro)

1994
- 1994-06-29 WO PCT/US1994/007476 patent/WO1995001455A1/en not_active Ceased
- 1994-06-29 AU AU73578/94A patent/AU7357894A/en not_active Abandoned
- 1994-06-29 EP EP94922483A patent/EP0714448B1/de not_active Expired - Lifetime
- 1994-06-29 AT AT94922483T patent/ATE237697T1/de not_active IP Right Cessation
- 1994-06-29 DE DE69432517T patent/DE69432517T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0714448A1 (de)	1996-06-05
EP0714448B1 (de)	2003-04-16
DE69432517T2 (de)	2003-12-24
DE69432517D1 (de)	2003-05-22
WO1995001455A1 (en)	1995-01-12
AU7357894A (en)	1995-01-24
EP0714448A4 (de)	1998-05-20

Similar Documents

Publication	Publication Date	Title
DE69635671D1 (de)	2006-02-02	Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
DE69828408D1 (de)	2005-02-03	Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
PL329922A1 (en)	1999-04-26	Quinoline carboxamides as inhibitors of the tumour necrosis factor and of phosphodiesterase
DK0836485T3 (da)	2002-09-30	Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
BR9408025A (pt)	1996-12-17	Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
ATE350030T1 (de)	2007-01-15	Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60036025D1 (de)	2007-09-27	Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten
ES2133807T3 (es)	1999-09-16	Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
ATE222769T1 (de)	2002-09-15	Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
DE3880118D1 (de)	1993-05-13	Verwendung eines mittels in form von mikrokapseln zur schabenbekaempfung.
WO1993021942A3 (en)	1994-01-20	Use of mmp inhibitors
DE69826695D1 (de)	2004-11-04	Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE79720T1 (de)	1992-09-15	Verfahren zur konservierung von transplantierbaren, in vitro kultivierten epithelgeweben.
BR9610480A (pt)	1999-03-16	Inibição do fator alfa de necrose tumoral
ATE428928T1 (de)	2009-05-15	Verfahren zur einführung von heterologischen zellen in fische
ATA903489A (de)	1995-06-15	Protoporphyrinogeninhibitoren und deren verwendung in zusammensetzungen zur erkennung und behandlung von tumoren
ATE382061T1 (de)	2008-01-15	Mittel zur induktion von apoptosis und zur therapieanwendung
HU9301677D0 (en)	1993-09-28	Polypeptide-type compounds of medical effect
DE69633393D1 (de)	2004-10-21	Mitteln zur behandlung von auto-immun krankheiten
ATE371031T1 (de)	2007-09-15	Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
DE69725882D1 (de)	2003-12-04	Adenovirus e4 proteine für induktion von zelltod
ATE173620T1 (de)	1998-12-15	Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ES473474A1 (es)	1979-10-01	Procedimiento para descubrir sustancias cancerigenas y subs-tancias anticancerosas
ATE237697T1 (de)	2003-05-15	Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit
MXPA02005069A (es)	2003-09-25	Agentes de enlace especificos para t3 y metodos para su uso.

Legal Events

Date	Code	Title	Description
2003-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties